Industry Themes

Next Generation CROs – Differentiated technologies today that will pay-off tomorrow

Historically, CROs have grown by building the scales for the services that pharma cos and biotechs wanted to outsource due to a number of reasons, from reducing the overheads, to cost-effective operations, to downsizing the headcount for effective management, etc. As a result, operational efficiency, large scales and past experiences have been the key value propositions, with relatively lesser focus on differentiated offerings, of course with a few exceptions. However, with BioPharma now riding on a wave of innovative technologies,…

Continue Reading

MP Group – Outlook of Protein Formulation Technologies – Opportunities for IV to subQ Conversion

Currently,~80% of biologics are administered intravenously due to high doses and challenges associated with high concentration protein formulation development – viscosity, stability including aggregation and volume. As a result, patients are tethered to IV infusion set-up for hours, few times a month often in a clinic or hospital, adding significant cost. Subcutaneous delivery enhances patient compliance and convenience, while significantly reducing the cost associated with hospitalization. Only a handful of technologies have attempted to address the protein formulation challenge, that…

Continue Reading

MP Group – Overview of Biobetters: IV to SC formulation conversion for patient compliance, healthcare savings, and market differentiation

The key highlights of the presentation are: Biobetters are an improved version of a biologic and provide better efficacy, safety and patient compliance while reducing the overall burden on healthcarePotential opportunity for Biosimilars company for marketplace differentiation and evasion of patent dance, and for Innovators to extend product lifecycle and delay biosimilars threatIntravenous (IV) to subcutaneous (SC) conversion is one of the most prudent strategies to address the unmet need of patient compliance while reducing the overall healthcare costsThe current…

Continue Reading

Japan Biosimilars: Landscape Today, Outlook Tomorrow – ‘Biosame’ entry, uninterrupted supply and companies’ strong front-end footprint requirements make it a distinct market

- After a decade, JP Biosimilar guideline’s first revision expected in FY2020 –Demonstrate Chuikyo need of biosimilar tool to curb healthcare cost - Biosimilars uptake varies as per each opportunity, Remicade BS vs. Rituxan BS- Two poles of the curve - A few skipping NHI listing due to manufacturing issues associated with constantsupply need, Japanese CDMO imminent to seal  this local need Since 2009, 25 biosimilars of 12 originator products are approved in Japan and have yielded mixed performances and…

Continue Reading

MP Group – Global Biosimilars Outlook, 2019

Year 2019 has been a pivotal year for biosimilars and it is our pleasure to share with you the Global Biosimilars Outlook, 2019, whichcovers in-depth analyses of biosimilars landscape across major geographies (EU, US, Japan, China and India) and presents ideas on how to move ahead in order to achieve global leadership in what we believe will be $40B market by 2025. EU Biosimilar Landscape: The most evolved market currently at a tipping point A matured biosimilar market, although with heterogeneous penetration across the member statesBetter prescriber incentives and multiple winning tenders will not…

Continue Reading

MP Group – Biosimilars Landscape – China and India

As you are exploring biosimilar opportunities, we would be delighted to share our insights to help you advance your strategy. Our active work has enabled us to develop an in depth understanding of the global biosimilar opportunity, and many of our forecasts of the past decade are now being realized. In fact, that is why the title of the attached slide deck is “Creating a global biosimilars leadership - Combining complementary strengths of China and India” (Click here to download) Global…

Continue Reading

MP Group – Biosimilars Landscape – USA

A pleasure to share with you the second issue of the Biosimilars series from MP Group. This issue covers in-depth analyses of the US biosimilars outlook, which includes market dynamics, evolving regulatory and policy landscape, competitive analysis, etc.    With 15+ biologics facing patent expiry by 2020, and ~25 more in the coming decade, ~$200+B biologics sales underpin the first wave of biosimilar opportunity, which is forecast to approach $500B around 2030. These high priced biologics contribute as much as one-half of healthcare…

Continue Reading

MP Advisors/Mehta Partners: Global Biosimilars Outlook -2019 & Beyond

It is our pleasure to share with you the first issue of the Biosimilars series from the MP Group. The series starts with macro perspective of the global biosimilars landscape and subsequent in-depth analyses of biosimilars outlook in various geographies, which includes market dynamics, evolving regulatory and policy landscape, product pipelines, competitive analysis, etc. Biosimilars are emerging as one of the most important sectors in the healthcare industry to curb increasing healthcare costs, primarily associated with biologics. With 15+ biologics…

Continue Reading

MP Advisors/Mehta Partners: Indian BioPharma Landscape – 2018

It is our pleasure to share with you our recent update on India's BioPharmaceutical Landscape. We have developed this evolving framework that has helped us assess various pharma markets and companies regardless of geography—an integrated perspective to help identify value drivers and global growth opportunities.  Indian companies have predominantly thrived on globalizing their generic formulations business with a primary focus on the US market.  However, increasing pricing pressure as a result of consolidation among payer groups and PBMs (Pharma Benefit Managers), and intensifying…

Continue Reading

Next Decade Generic String Of Pearls Opportunities: Sustainability Assessment With Respect To Therapeutic Positioning

The rapid growth of the generic industry has come with a number of challenges, such as heavy competition, including from authorized generics and government-mandated price cuts. All contribute to diminishing prices and ever decreasing margins. In this era of increased pharmaceutical industry competition, success for generic drug companies is dependent on their ability to manufacture therapeutic-equivalent drug products in an economical and timely manner, while also being cognizant of patent infringement and other legal and regulatory concerns. Diversification of product…

Continue Reading
Close Menu